Merck & Co., Inc.
Annual return
—
SPY
—
Alpha
—
Invested
$349.4M
Holdings
12
Trades YTD
0
Performance · Fund vs SPY
Cumulative return · quarterly snapshotsCoverage 98%. 2 quarters of 2025 measured against SPY adj-close benchmark.
Top holdings · current snapshot
Source: 13F-HR01
$MRNA
MODERNA INC
Q4 2024: New position (2.31M shares)
36.6%
02
$PSNL
PERSONALIS INC
Q4 2024: New position (14.04M shares)
27.9%
03
$KYMR
KYMERA THERAPEUTICS INC
Q4 2024: New position (772.2k shares)
20.1%
04
$EIKN
EIKON THERAPEUTICS INC
Held since at least Q1 2024
5.5%
05
$AKTS
AKTIS ONCOLOGY INC
Held since at least Q1 2024
5.3%
06
$ALEC
ALECTOR INC
Q4 2024: New position (3.55M shares)
2.4%
07
$EVAXUSD
EVAXION BIOTECH A/S
Q1 2025: Increased +123.9% (542.3k → 1.21M shares)
1.4%
08
$VRDN
VIRIDIAN THERAPEUTICS INC
Q4 2024: New position (93.4k shares)
0.6%
09
$XLO
XILIO THERAPEUTICS INC
Q4 2024: New position (1.48M shares)
0.3%
10
$CARM
CARISMA THERAPEUTICS INC
Q4 2024: New position (1.47M shares)
0.0%
Recent trades · Last 90 days
No Form 4 / 13D / 13G trade events on file in the recent window. 13F filers report position snapshots quarterly rather than per-trade events, so this section is most useful for managers who also file Form 4 or 13D/G.
Convergence · Pattern Engine ships in v1.1
30-day windowIn development
Convergence participation lands with the Pattern Engine.
Once the Pattern Engine ships, this section will list every active convergence event this fund is named in — with the other named funds, the Congress members on the same name, and combined position size.
Source data: SEC EDGAR · 13F-HR filings · Last refreshed 10:15 UTC.